Ceribell, Inc.

Based on the Company s current operating plan, the Company believes that its existing cash and cash equivalents and marketable securities will be sufficient to fund the Company s planned operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these financial statements.

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026

However, the Company may experience lower than expected cash generated from operating activities or greater than expected capital expenditures, cost of revenue, or operating expenses, and may need to raise additional capital to fund operations, further research and development activities, or acquire, invest in, or license other businesses, assets, or technologies.

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Term Loan 2024 Term Loan In consideration of the 2024 principal loan repayment schedule and future operating cash flow requirements, effective February 6, 2024, the Company executed a Venture Loan and Security Agreement ( VLSA ) with Horizon Technology Finance Corporation ( Horizon ) as a lender and the collateral agent and Silicon Valley Bank ( SVB ) as a lender (collectively, the Lenders ).

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Upon execution of the VLSA, the Company drew down the entire first tranche of $ 20.0 million in principal ( Term Loan ), including $ 6.0 million from SVB ( SVB Loan ) and $ 14.0 million from Horizon ( Horizon Loan ).

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026

The Term Loan is payable to the Lenders in twelve equal monthly installments between April 1, 2028 ( Amortization Date ) and March 1, 2029 ( Maturity Date ) subject to certain prepayment fees in accordance with the VLSA.

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026

No borrowings were made under the Revolving Facility, and the Revolving Facility is no longer available for borrowing.

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026

(Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025.

SEC original ↗Ceribell, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

“As we look to the second half of 2025, we believe we are well-positioned to drive continued growth and propel key strategies to reach more patients, advance our pipeline, and reinforce our category leadership while establishing EEG as a new vital sign.

SEC original ↗Ceribell, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The increase was primarily driven by continued commercial traction within our core market, resulting from adoption by new accounts and continued expansion within the company’s active account base.

SEC original ↗Ceribell, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

This earnings release and the related attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, the anticipated rate and impact of tariffs on our estimated gross margins; our finished goods headband product inventory and the duration of supply of finished goods; revenue associated with subscription products; our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; expectations for our products; and other statements that are not statements of historical fact.

SEC original ↗Ceribell, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions.

SEC original ↗Ceribell, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any potential outcome expressed in these forward-looking statements will be realized in whole or in part.

SEC original ↗Ceribell, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Ceribell’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

SEC original ↗Ceribell, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 30 Item 1A.

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026

Exhibits 78 Signatures i Table of Contents Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties.

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026

The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, and other factors described in the section titled Risk Factors and elsewhere in this Quarterly Report on Form 10-Q.

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026

New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q.

SEC original ↗Ceribell, Inc. — 10-Q Quarterly report10-QAug 10, 2026